ABSTRACT
Purpose A subset of patients with post-COVID-19 condition (PCC) fulfill the clinical criteria of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). To establish the diagnosis of ME/CFS for clinical and research purposes, comprehensive scores have to be evaluated.
Methods We developed the Munich Berlin Symptom Questionnaires (MBSQs) and supplementary scoring sheets (SSSs) to allow for a rapid evaluation of common ME/CFS case definitions. The MBSQs were applied to young patients with chronic fatigue and post-exertional malaise (PEM) who presented to the MRI Chronic Fatigue Center for Young People (MCFC). Trials were retrospectively registered (NCT05778006, NCT05638724).
Results Using the MBSQs and SSSs, we report on ten patients aged 11 to 25 years diagnosed with ME/CFS after asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19. Results from their MBSQs and from well-established patient-reported outcome measures indicated severe impairments of daily activities and health-related quality of life.
Conclusions ME/CFS can follow SARS-CoV-2 infection in patients younger than 18 years, rendering structured diagnostic approaches most relevant for pediatric PCC clinics. The MBSQs and SSSs represent novel diagnostic tools that can facilitate the diagnosis of ME/CFS in children, adolescents, and adults with PCC and other post-viral syndromes.
What is known ME/CFS is a frequent debilitating illness. For diagnosis, an extensive differential diagnostic workup is required and the evaluation of clinical ME/CFS criteria. ME/CFS following COVID-19 has been reported in adults but not in pediatric patients younger than 19 years of age.
What is new We present novel questionnairs (MBSQs), as tools to assess common ME/CFS case definitions in pediatric and adult patients with post-COVID-19 condition and beyond. We report on ten patients aged 11 to 25 years diagnosed with ME/CFS following asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19.
Competing Interest Statement
U.B. received research grants from the Federal Ministry of Education and Research (BMBF), the Federal Ministry of Health (BMG), the Bavarian Ministry of Health and Care (StMGP), the Bavarian Ministry of Science and Arts (StMWK), the German Center for Infection Research (DZIF), the People for Children (Menschen fuer Kinder) foundation, the Weidenhammer-Zoebele foundation, the Lost-Voices foundation, and the ME/CFS research foundation. C.S. was consulting Roche, Celltrend, and Bayer; she received support for clinical trials by Bayer, Fresenius, and Miltenyi, honoraria for lectures by Fresenius, AstraZeneca, BMS, Roche, Bayer, and Novartis, and research grants from the German Research Association (DFG), the BMBF, the BMG, the Weidenhammer-Zoebele foundation, the Lost-Voices foundation, and the ME/CFS research foundation. The other authors declare no conflict of interest.
Funding Statement
This work was supported by the Bavarian Ministry of Health and Care, the Weidenhammer-Zoebele, and the Lost-Voices foundations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the Technical University of Munich gave ethical approval for this work (116/21, 511/21).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- ANA
- antinuclear antibodies
- CCC
- Canadian consensus criteria
- CDC
- Centers of Disease Control and Prevention
- CDW-R
- clinical diagnostic worksheet of P.C. Rowe et al. (2017)
- CFC
- Charité Fatigue Center
- COVID-19
- coronavirus disease 2019
- CRP
- C-reactive protein
- DSQ
- DePaul symptom questionnaire
- EBV
- Epstein-Barr virus
- ECG
- electrocardiography
- EEG
- electroencephalography
- EUROMENE
- European Network on ME/CFS
- GET
- graded exercise therapy
- HR
- heart rate
- HRQoL
- health-related quality of life
- IOM
- Institute of Medicine
- KBV
- German National Association of Statutory Health Insurance Physicians
- MBSQ
- Munich Berlin Symptom Questionnaire
- MCFC
- MRI Chronic Fatigue Center for Young People
- ME/CFS
- myalgic encephalomyelitis / chronic fatigue syndrome
- MRI
- TUM university hospital (Klinikum rechts der Isar)
- MRT
- magnetic resonance tomography
- NICE
- National Institute for Health and Care Excellence
- OH
- orthosthatic hypotension
- OI
- orthosthatic intolerance
- PASC
- post-acute sequelae of COVID-19
- PCC
- post-COVID-19 condition
- PCD-J
- pediatric case definition by L.A. Jason et al. (2006)
- PEM
- post-exertional malaise
- PFT
- pulmonary function testing
- PoTS
- postural tachcardia syndrome
- PROM
- patient-reported outcome measure
- RT-PCR
- reverse transcriptase - polymerase chain reaction
- SARS-CoV-2
- severe acute respiratory coronavirus type 2
- SEID
- systemic exertion intolerance disease criteria
- SF-36
- Short Form 36
- SSS
- Supplementary Scoring Sheet
- UCG
- ultrasound cardiography
- WHO
- World Health Organisation
